{"id":"neurostat","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Hypertension"}]},"_chembl":null,"_dailymed":{"setId":"028d842f-3abd-421e-b6b8-07313ef690b8","title":"NEUROSTAT (CIMICIFUGA RACEMOSA, AGARICUS MUSCARIUS, COCCUS CACTI, CONIUM MACULATUM, CUPRUM METALLICUM, GELSEMIUM SEMPERVIRENS, LYCOPODIUM CLAVATUM, PHOSPHORUS, RHUS TOX, TARENTULA CUBENSIS, LATRODECTUS MACTANS, PYROGENIUM) LIQUID [ENERGIQUE, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"NeuroSTAT® (dexamethasone sodium phosphate formulated for neuroprotection) works by preserving mitochondrial membrane potential and preventing the opening of the mitochondrial permeability transition pore, which is a key mechanism of cell death in acute neurological injury. By maintaining mitochondrial integrity during ischemia and reperfusion, the drug reduces excitotoxicity and apoptosis in neural tissue.","oneSentence":"NeuroSTAT® protects mitochondrial function and reduces neuronal damage by stabilizing the inner mitochondrial membrane during ischemic stress.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T06:40:31.315Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute ischemic stroke"},{"name":"Cardiac surgery-associated neurological complications"}]},"trialDetails":[{"nctId":"NCT01825044","phase":"PHASE2","title":"Copenhagen Head Injury Ciclosporin (CHIC) Study","status":"COMPLETED","sponsor":"NeuroVive Pharmaceutical AB","startDate":"2013-04","conditions":"Traumatic Brain Injury","enrollment":16},{"nctId":"NCT01692834","phase":"PHASE1","title":"A Study to Compare the Bioavailability and Pharmacokinetics of Cyclosporine After Intravenous Administration of NEUROSTAT®, a CREMOPHOR® EL-free Lipid Emulsion, and SANDIMMUNE® Injection (a Suspension of Cyclosporine in CREMOPHOR® EL) in Healthy Volunteers","status":"COMPLETED","sponsor":"NeuroVive Pharmaceutical AB","startDate":"2009-06","conditions":"Healthy","enrollment":65}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":48,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["CicloMulsion® (ready-to-use lipid emulsion of Cyclosporine A)"],"phase":"marketed","status":"active","brandName":"NeuroSTAT®","genericName":"NeuroSTAT®","companyName":"NeuroVive Pharmaceutical AB","companyId":"neurovive-pharmaceutical-ab","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NeuroSTAT® protects mitochondrial function and reduces neuronal damage by stabilizing the inner mitochondrial membrane during ischemic stress. Used for Acute ischemic stroke, Cardiac surgery-associated neurological complications.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}